Scientists may have uncovered a completely new way to fight rheumatoid arthritis using a natural substance found in a traditional medicinal plant.
Their study, published in Engineering, found that obakulactone reduced joint damage in laboratory research by changing how cells handle fats and inflammation.
Rheumatoid arthritis affects about one percent of the world’s population. Unlike osteoarthritis, which results from wear and tear, rheumatoid arthritis develops when the immune system attacks healthy joint tissue. Over time this can damage cartilage, bone, and other organs if the disease is not controlled.
Current medicines can slow the disease, but they do not work for everyone and may cause serious side effects. Researchers are therefore searching for new treatments that target different biological processes.
In this study, researchers treated rats with rheumatoid arthritis using several doses of obakulactone over 21 days. The treated animals showed less swelling, healthier joint tissue, and fewer signs of immune system overactivity than untreated animals.
The scientists also studied joint cells in the laboratory. Normally these cells multiply too quickly and release chemicals that drive inflammation. Obakulactone slowed their growth, encouraged damaged cells to die naturally, and reduced the release of inflammatory molecules.
Further experiments revealed that the compound restored healthier levels of important unsaturated fatty acids, including arachidonic acid, linoleic acid, and alpha-linolenic acid. These fats help regulate many normal body functions and appear to become unbalanced during rheumatoid arthritis.
A major breakthrough came when researchers identified ACOT1 as the direct target of obakulactone. The compound marked this protein for destruction through the cell’s natural recycling system. This reduced activity in several signaling pathways that normally promote inflammation, tissue damage, and scarring.
These findings suggest that changing fatty acid metabolism could become an entirely new strategy for treating rheumatoid arthritis rather than simply blocking inflammation. It also opens the possibility of developing medicines that specifically target ACOT1.
Although the results are exciting, they represent an early stage of research. Human clinical trials will be necessary to determine whether obakulactone is safe, effective, and able to provide long-term benefits for people living with rheumatoid arthritis.
This research provides encouraging early evidence that obakulactone may reduce inflammation and joint damage by targeting fatty acid metabolism and a protein called ACOT1.
However, the work was carried out in rats and laboratory cells, so it cannot show that the treatment will work in people. Clinical studies will be needed before obakulactone can be considered as a new treatment for rheumatoid arthritis.
If you care about pain, please read studies that vegetarian women have higher risk of hip fracture, and these vitamins could help reduce bone fracture risk.
For more information about wellness, please see recent studies that Krill oil could improve muscle health in older people, and Jarlsberg cheese could help prevent bone thinning disease.
Source: Engineering.
